SPX3,783.28-7.65 -0.20%
DIA302.79-0.35 -0.12%
IXIC11,148.64-27.77 -0.25%

BRIEF-Oramed Reports Positive Top-Line Results From Phase 2 NASH Trial

BRIEF-Oramed Reports Positive Top-Line Results From Phase 2 NASH Trial

Reuters · 09/13/2022 09:49
BRIEF-Oramed Reports Positive Top-Line Results From Phase 2 NASH Trial

- Oramed Pharmaceuticals Inc ORMP.O:

  • ORAMED REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE 2 NASH TRIAL WITH ITS ORMD-0801, ORAL INSULIN CANDIDATE

  • ORAMED PHARMACEUTICALS INC - PRIMARY ENDPOINT MET: ORMD-0801 WAS SAFE AND WELL TOLERATED

  • ORAMED PHARMACEUTICALS INC - SECONDARY ENDPOINT MET: ORMD-0801 SHOWED CLINICALLY MEANINGFUL REDUCTION OF LIVER FAT FROM BASELINE AT 12 WEEKS

  • ORAMED PHARMACEUTICALS INC - AWAIT TOP-LINE DATA FROM PHASE 3 TRIAL OF ORAL INSULIN FOR T2D, WHICH WE EXPECT IN JANUARY 2023

Source text for Eikon: ID:

Further company coverage: ORMP.O


((Reuters.Briefs@thomsonreuters.com;))